The effect of royal jelly on the growth of breast cancer in mice

  • Authors:
    • Shuang Zhang
    • Qiqi Shao
    • Haiyang Geng
    • Songkun Su
  • View Affiliations

  • Published online on: September 27, 2017     https://doi.org/10.3892/ol.2017.7078
  • Pages: 7615-7621
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Due to various pharmacological properties, including antioxidative, anti‑inflammatory and antibiotic properties, royal jelly (RJ) has been widely consumed in daily diets in numerous countries. In the present study, the effect of RJ on 4T1‑bearing mice was investigated. The study was performed by feeding 4T1‑bearing mice with RJ using either the prophylactic‑therapeutic (PTRJ) or therapeutic (TRJ) method. The experimental results for the PTRJ group demonstrated that the weight of tumor was significantly reduced (RJ 0.5 and 1.5 g/kg); and in the serum, the levels of interleukin (IL)‑2 (RJ 0.5 and 1.5 g/kg), interferon (IFN)‑α, superoxide dismutase (SOD) and total antioxidant capacity (T‑AOC) were significantly elevated, but the concentrations of IL‑4 (RJ 0.5 and 1.5 g/kg) and IL‑10 (RJ 1.0 g/kg) were significantly decreased. In addition, the activities of T‑AOC and glutathione reductase (GR) were significantly improved in the liver, whereas in the kidney, the activities of T‑AOC and GR were significantly increased only under the dose of 0.5 g/kg. For the TRJ group, the antitumor effect of RJ was not significant; the change in IL‑2, IFN‑α, SOD and T‑AOC levels in the serum, and the change in T‑AOC and GR in liver were similar to those observed in the PTRJ groups. RJ treatment was demonstrated to reduce the development of breast tumor in mice, and simultaneously improve the antioxidant capacity of the serum, liver and kidney, particularly using the prophylactic‑therapeutic method. These results corroborated the efficacy of RJ supplementation in diets. The results of the present study suggest that the antioxidant and immunomodulatory activities of RJ serve an important role on antitumor growth.

References

1 

Isidorov V, Czyżewska U, Isidorova A and Bakier S: Gas chromatographic and mass spectrometric characterization of the organic acids extracted from some preparations containing lyophilized royal jelly. J Chromatogr B Analyt Technol Biomed Life Sci. 877:3776–3780. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T and Kobayashi K: A potent antibacterial protein in royal jelly. purification and determination of the primary structure of royalisin. J Biol Chem. 265:11333–11337. 1990.PubMed/NCBI

3 

Karaca T, Uz YH, Demirtas S, Karaboga I and Can G: Protective effect of royal jelly in 2,4,6 trinitrobenzene sulfonic acid-induced colitis in rats. Iran J Basic Med Sci. 18:370–379. 2015.PubMed/NCBI

4 

Arzi A, Olapour S, Yaghooti H and Karampour Sistani N: Effect of royal jelly on formalin induced-inflammation in rat hind paw. Jundishapur J Nat Pharm Prod. 10:e224662015. View Article : Google Scholar : PubMed/NCBI

5 

Yildirim S, Karadeniz A, Karakoc A, Yildirim A, Kalkan Y and Şimşek N: Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin. Turk J Med Sci. 42:367–375. 2012.

6 

Niu K, Guo H, Guo Y, Ebihara S, Asada M, Ohrui T, Furukawa K, Ichinose M, Yanai K, Kudo Y, et al: Royal jelly prevents the progression of sarcopenia in aged mice in vivo and in vitro. J Gerontol A Biol Sci Med Sci. 68:1482–1492. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Nomura M, Maruo N, Zamami Y, Takatori S, Doi S and Kawasaki H: Effect of long-term treatment with royal jelly on insulin resistance in otsuka long-evans tokushima fatty (OLETF) rats. Yakugaku Zasshi. 127:1877–1882. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Kashima Y, Kanematsu S, Asai S, Kusada M, Watanabe S, Kawashima T, Nakamura T, Shimada M, Goto T and Nagaoka S: Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly. PLoS One. 9:e1050732014. View Article : Google Scholar : PubMed/NCBI

9 

Nakaya M, Onda H, Sasaki K, Yukiyoshi A, Tachibana H and Yamada K: Effect of royal jelly on bisphenol A-induced proliferation of human breast cancer cells. Biosci Biotechnol Biochem. 71:253–255. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Salazar-Olivo L and Paz-González V: Screening of biological activities present in honeybee (Apis mellifera) royal jelly. Toxicol In Vitro. 19:645–651. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Oršolić N, Terzić S, Šver L and Bašić I: Honey-bee products in prevention and/or therapy of murine transplantable tumours. J Sci Food Agric. 85:363–370. 2005. View Article : Google Scholar

12 

Šimúth J, Bíliková K, Kováčová E, Kuzmová Z and Schroder W: Immunochemical approach to detection of ddulteration in honey: Physiologically active royal jelly protein stimulating TNF-alpha release is a regular component of honey. J Agric Food Chem. 52:2154–2158. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Mishima S, Suzuki KM, Isohama Y, Kuratsu N, Araki Y, Inoue M and Miyata T: Royal jelly has estrogenic effects in vitro and in vivo. J Ethnopharmacol. 101:215–220. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Suzuki KM, Isohama Y, Maruyama H, Yamada Y, Narita Y, Ohta S, Araki Y, Miyata T and Mishima S: Estrogenic activities of fatty acids and a sterol isolated from royal jelly. Evid Based Complement Alternat Med. 5:295–302. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP and Sherman ME: Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 13:1558–1568. 2004.PubMed/NCBI

16 

Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Iwase H: Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol. 20:249–252. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Taavoni S, Barkhordari F, Goushegir A and Haghani H: Effect of Royal Jelly on premenstrual syndrome among Iranian medical sciences students: A randomized, triple-blind, placebo-controlled study. Complement Ther Med. 22:601–606. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Pulaski BA and Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res. 58:1486–1493. 1998.PubMed/NCBI

20 

Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Luo KW, Ko CH, Yue GG, Lee JK, Li KK, Lee M, Li G, Fung KP, Leung PC and Lau CB: Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice. J Nutr Biochem. 25:395–403. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Bincoletto C, Eberlin S, Figueiredo CA, Luengo MB and Queiroz ML: Effects produced by royal jelly on haematopoiesis: Relation with host resistance against ehrlich ascites tumour challenge. Int Immunopharmacol. 5:679–688. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Tamura T, Fujii A and Kuboyama N: Antitumor effects of royal jelly (RJ). Nihon Yakurigaku Zasshi. 89:73–80. 1987.(In Japanese). View Article : Google Scholar : PubMed/NCBI

24 

Shirzad M, Kordyazdi R, Shahinfard N and Nikokar M: Does royal jelly affect tumor cells ? J HerbMed Pharmacol. 2:45–48. 2013.

25 

Townsend GF, Morgan JF and Hazlett B: Activity of 10-hydroxydecenoic acid from royal jelly against experimental leukaemia and ascitic tumours. Nature. 183:1270–1271. 1959. View Article : Google Scholar : PubMed/NCBI

26 

Townsend GF, Morgan JF, Tolnai S, Hazlett B, Morton HJ and Shuel RW: Studies on the in vitro antitumor activity of fatty acids I. 10-hydroxy-2-decenoic acid from royal jelly. Cancer Res. 20:503–510. 1960.PubMed/NCBI

27 

Male D: Reactions against blood cells and plateletsInL Immunology. 4th Edition. Roitt I, Brostoff J and Male D: Mosby; London: pp. 3–23. 1996

28 

Liu RM, Zhang XJ, Liang GY, Yang YF, Zhong JJ and Xiao JH: Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom cordyceps taii in mouse models. BMC Complement Altern Med. 15:2162015. View Article : Google Scholar : PubMed/NCBI

29 

Murugaiyan G and Saha B: IL-27 in tumor immunity and immunotherapy. Trends Mol Med. 19:108–116. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, et al: Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72:5188–5197. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, et al: Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 133:771–778. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, Bondanza A, Gentner B, De Palma M, Mazzieri R and Naldini L: Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci Transl Med. 6:217ra32014. View Article : Google Scholar : PubMed/NCBI

33 

Gasic S, Vucevic D, Vasilijic S, Antunovic M, Chinou I and Colic M: Evaluation of the immunomodulatory activities of royal jelly components in vitro. Immunopharmacol Immunotoxicol. 29:521–536. 2007. View Article : Google Scholar : PubMed/NCBI

34 

Okamoto I, Taniguchi Y, Kunikata T, Kohno K, Iwaki K, Ikeda M and Kurimoto M: Major royal jelly protein 3 modulates immune responses in vitro and in vivo. Life Sci. 73:2029–2045. 2003. View Article : Google Scholar : PubMed/NCBI

35 

Oka H, Emori Y, Kobayashi N, Hayashi Y and Nomoto K: Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses. Int Immunopharmacol. 1:521–532. 2001. View Article : Google Scholar : PubMed/NCBI

36 

Erem C, Deger O, Ovali E and Barlak Y: The effects of royal jelly on autoimmunity in Graves' disease. Endocrine. 30:175–183. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, Redman K, Munday H, Easton DF, Dunning AM and Ponder BA: Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res. 66:1225–1233. 2006. View Article : Google Scholar : PubMed/NCBI

38 

Şener DE, Gönenç A, Akıncı M and Torun M: Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct. 25:377–382. 2007. View Article : Google Scholar : PubMed/NCBI

39 

Samy RP, Gopalakrishnakone P and Ignacimuthu S: Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chem Biol Interact. 164:1–14. 2006. View Article : Google Scholar : PubMed/NCBI

40 

Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, Kisa F, Emre H and Turkeli M: Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxid Med Cell Longev. 2011:9817932011. View Article : Google Scholar : PubMed/NCBI

41 

Jamnik P, Goranovič D and Raspor P: Antioxidative action of royal jelly in the yeast cell. Exp Gerontol. 42:594–600. 2007. View Article : Google Scholar : PubMed/NCBI

42 

Gómez-Caravaca AM, Gómez-Romero M, Arráez-Román D, Segura-Carretero A and Fernández-Gutiérrez A: Advances in the analysis of phenolic compounds in products derived from bees. J Pharm Biomed Anal. 41:1220–1234. 2006. View Article : Google Scholar : PubMed/NCBI

43 

Da Silva RJ, Da Silva MG, Vilela LC and Fecchio D: Cytokine profile of ehrlich ascites tumor treated with Bothrops jararaca venom. Mediators Inflamm. 11:197–201. 2002. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, S., Shao, Q., Geng, H., & Su, S. (2017). The effect of royal jelly on the growth of breast cancer in mice. Oncology Letters, 14, 7615-7621. https://doi.org/10.3892/ol.2017.7078
MLA
Zhang, S., Shao, Q., Geng, H., Su, S."The effect of royal jelly on the growth of breast cancer in mice". Oncology Letters 14.6 (2017): 7615-7621.
Chicago
Zhang, S., Shao, Q., Geng, H., Su, S."The effect of royal jelly on the growth of breast cancer in mice". Oncology Letters 14, no. 6 (2017): 7615-7621. https://doi.org/10.3892/ol.2017.7078